Market
How many countries will be conducting DBS trials for spinal cord injury by end of 2025?
2
Resolution / Starting Odds
1-2 countries • 25%
3-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Global clinical trial registries and publications
Story
Swiss Researchers Restore Walking in Paraplegic Patients with Brain Stimulation Targeting Lateral Hypothalamus
Dec 2, 2024, 05:15 PM
Swiss researchers have achieved a groundbreaking medical advancement by enabling two paraplegic patients with partial spinal cord injuries to walk again using deep brain stimulation (DBS). The technique involves implanting electrodes in the lateral hypothalamus, a brain region not traditionally associated with movement, to stimulate neural activity. This innovative approach has shown promising results, allowing the patients to walk short distances, climb stairs, and improve lower limb movements. The study, published in Nature Medicine, also demonstrated similar recovery outcomes in preclinical models, including mice and rats. These findings highlight the potential of DBS as a transformative therapy for spinal cord injury rehabilitation.
View original story
Similar markets
Other • 25%
European Union • 25%
United States • 25%
China • 25%
None of the above • 25%
FDA approval • 25%
Widespread clinical trials • 25%
Full mobility restoration in a patient • 25%
Johns Hopkins Hospital • 25%
Mayo Clinic • 25%
Other • 25%
Cleveland Clinic • 25%
Yes • 50%
No • 50%
More than 15 countries • 25%
11 to 15 countries • 25%
6 to 10 countries • 25%
1 to 5 countries • 25%
1-2 countries • 25%
More than 6 countries • 25%
5-6 countries • 25%
3-4 countries • 25%
Switzerland • 25%
Other • 25%
France • 25%
Germany • 25%
11 to 15 • 25%
More than 15 • 25%
Less than 5 • 25%
5 to 10 • 25%
4-6 countries • 25%
10 or more countries • 25%
7-9 countries • 25%
1-3 countries • 25%
3 to 4 international approvals • 25%
5 or more international approvals • 25%
1 to 2 international approvals • 25%
No international approvals • 25%